Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 11;72(8):2783–2797. doi: 10.1007/s00262-023-03459-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — Docetaxel and NHS-IL-12 combination therapy sets up an immune-stimulatory tumor microenvironment. MC38 tumor-bearing mice treated as in Fig. 3A were sacrificed on day 17 post-tumor implant and tumor whole transcriptome analysis was performed. Gene set enrichment analysis was carried out for docetaxel and NHS-IL-12 combination therapy versus untreated tumors. (A) Heatmap of bulk-RNA-seq data collected on day 17 post-treatment showing the top 30 upregulated and downregulated transcripts in MC38 tumors treated with monotherapy versus combination therapy, normalized to tumor expression with PBS treatment. (B) Transcriptomic analysis of combination-treated tumors shows significant enrichment in pathways associated with tumor suppression. Data represent one experiment, n = 3–4 mice/group. Fisher’s test for pathways applied top 10% genes with p value cut-off of p = 0.05. GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes